2021.11.23
On November 21st 2021, Jiangsu Hengrui Medicines Co., Ltd. (A-share Code: 600276) ("Hengrui Medicines") and Cstone Pharmaceuticals (Suzhou) Co., Ltd. (Hong Kong share code: 02616) ("Cstone Pharmaceuticals") announced that they had reached an exclusive license agreement. Hengrui Medicines will receive the exclusive license for the R & D, registration, production and commercialization of the anti-CTLA-4 monoclonal antibody (CS1002) in Greater China (including mainland China, Taiwan, Hongkong and Macao).
Hengrui Medicines is a national pharmaceutical enterprise engaged in the development and promotion of innovative and high-quality drugs. It has developed into a well-known supplier of antineoplastic drugs, surgical drugs and imaging intervention products in China. Cstone Pharmaceuticals is a biopharmaceutical company focusing on the research, development and commercialization of innovative tumor immunotherapy and precision therapy drugs to meet the medical needs of cancer patients in China and around the world.
JunHe was entrusted by Hengrui Medicines to review, modify and negotiate the transaction documents. During this transaction, JunHe made full use of its vast practical experience in the pharmaceutical field and provided its valued clients with high-quality, rigorous and efficient legal services. The team won high praise from Hengrui Medicines.
This project was led by Partner Mr. ZHAO, Hao (Gerry).
